Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Increases Circulating Zinc-Α(2)-Glycoprotein Levels in Patients with Type 2 Diabetes

ZAG has recently been characterized as a potent metabolic regulator, but the effect of anti-diabetic agents on ZAG in humans remains unknown. Our aim was to study the effects of SGLT2 inhibitor on circulating ZAG and ADI in nT2DM. 162 subjects with nT2DM were treated by a placebo or DAPA. After 3-mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Xin, Wang, Xuemei, Li, Haopeng, Li, Ling, Zhang, Guohao, Yang, Mengliu, Yuan, Lei, Liu, Hua, Yang, Gangyi, Gao, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017191/
https://www.ncbi.nlm.nih.gov/pubmed/27611858
http://dx.doi.org/10.1038/srep32887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017191/
https://www.ncbi.nlm.nih.gov/pubmed/27611858
http://dx.doi.org/10.1038/srep32887

Ejemplares similares